二甲双胍联合DPP-4抑制剂与二甲双胍单药治疗2型糖尿病的疗效比较

摘要

Objective To investigate the therapeutic comparison between pure metformin and DPP-4 inhibitors as add-on therapy to metformin in the newly diagnosed T2DM patients. Methods The 200 newly diagnosed TZDM patients were randomized into observation group and control group. Both of the two groups were given metformin while the observation group was administered DPP-4 inhibitors additionally for 24 weeks. The fasting plasma glucose (FPG), two-hour postprandial plasma glucosc (2 hPG hemoglobin A1c(HbA1c)> body mass index(BM1), and the incidence of hypoglycemia in both groups were observed. Results Compared with the control group, the levels of FPG 2 hPG, and HbA1c decreased significantly in the observation group(P<0. 05). The targeting rate of HbAj c was 85 % in the observation group, significantly higher than 72% in the control group(P<0. 05). The change in BMI and the incidence of hypoglycemia of the two groups were not significantly different (P>0. 05). Conclusion The combination of metformin with DPP-4 inhibitors is more effective for the treatment of T2DM, without influence on the body weight, and without increased risk for incidence of hypoglycemia.%目的 探讨对新诊断T2DM患者给予二肽基肽(DPP-4)抑制剂联合口服药降糖方案的有效性及安全性. 方法 收集200例新诊断T2DM患者,随机分为观察组和对照组,对照组采用二甲双胍常规治疗,观察组加用DPP-4抑制剂,随访24周,观察FPG、2 hPG和HbA1c等有效性指标及BMI,低血糖发生情况. 结果 观察组治疗后FPG和HbA1c相较于对照组显著下降(P＜0.05),观察组HbA1c达标率为85％显著高于对照组的72％(P＜0.05),两组治疗后BMI及低血糖发生率无显著差异(P＞0.05). 结论 DPP-4抑制剂与二甲双胍联用治疗T2DM降糖效果更好,对体重无影响,不会增加低血糖风险.